Apoptosis as a mechanism for liver disease progression

Seminars in Liver Disease

Volumn 30, Issue 4, 2010, Pages 402-410

  Guicciardi, Maria Eugenia ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bcl 2 proteins; caspase inhibitors; death receptors; stellate cells; Toll like receptor 9

Indexed keywords

CASPASE INHIBITOR; TOLL LIKE RECEPTOR 9;

ACUTE GRAFT REJECTION; APOPTOSIS; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; CELL DEATH; CLINICAL PRACTICE; CPG ISLAND; DISEASE COURSE; DRUG INDUCED DISEASE; EXPERIMENTAL MOUSE; FIBROGENESIS; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; MEDIATOR RELEASE; MOLECULAR MECHANICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHAGOCYTE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; STELLATE CELL; VIRUS HEPATITIS; WILSON DISEASE;

APOPTOSIS; CASPASES; DISEASE PROGRESSION; DNA DAMAGE; GENES, BCL-2; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; LIVER DISEASES; PHAGOCYTOSIS; TOLL-LIKE RECEPTOR 9;

EID: 77958166518     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0030-1267540     Document Type: Review

References (98)

1. Kim W R., Flamm S L., Di Bisceglie A M., Bodenheimer H C., Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008 47 (4) 1363-1370
2. Rust C, Gores G J. Apoptosis and liver disease. Am J Med 2000 108 (7) 567-574
3. Canbay A, Friedman S, Gores G J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004 39 (2) 273-278
4. Kerr J F., Wyllie A H., Currie A R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972 26 (4) 239-257
5. Grassi A, Susca M, Ferri S et al. Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embedded sections. Am J Clin Pathol 2004 121 (2) 211-219
6. Pop C, Salvesen G S. Human caspases: activation, specificity, and regulation. J Biol Chem 2009 284 (33) 21777-21781
7. Oberst A, Pop C, Tremblay A G. et al. Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J Biol Chem 2010 285 (22) 16632-16642
8. Canbay A, Feldstein A, Baskin-Bey E, Bronk S F., Gores G J. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004 308 (3) 1191-1196
9. Wieckowska A, Zein N N., Yerian L M., Lopez A R., McCullough A J., Feldstein A E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006 44 (1) 27-33
10. Taylor R C., Cullen S P., Martin S J. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008 9 (3) 231-241
11. Malhi H, Guicciardi M E., Gores G J. Hepatocyte death: a clear and present danger. Physiol Rev 2010 90 (3) 1165-1194
12. Malhi H, Gores G J. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008 134 (6) 1641-1654
13. Wei M C., Zong W X., Cheng E H. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001 292 (5517) 727-730
14. Youle R J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008 9 (1) 47-59
15. Du C, Fang M, Li Y, Li L, Wang X. SMAC, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000 102 (1) 33-42
16. Guicciardi M E., Gores G J. Life and death by death receptors. FASEB J 2009 23 (6) 1625-1637
17. Faubion W A., Gores G J. Death receptors in liver biology and pathobiology. Hepatology 1999 29 (1) 1-4
18. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998 94 (4) 481-490
19. Li H, Zhu H, Xu C J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998 94 (4) 491-501
20. Akazawa Y, Gores G J. Death receptor-mediated liver injury. Semin Liver Dis 2007 27 (4) 327-338
21. Chisari F V. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997 99 (7) 1472-1477
22. Sodeman T, Bronk S F., Roberts P J., Miyoshi H, Gores G J. Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol 2000 278 (6) G992-G999
23. Faubion W A., Guicciardi M E., Miyoshi H et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999 103 (1) 137-145
24. Higuchi H, Bronk S F., Taniai M, Canbay A, Gores G J. Cholestasis increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. J Pharmacol Exp Ther 2002 303 (2) 461-467
25. Natori S, Rust C, Stadheim L M., Srinivasan A, Burgart L J., Gores G J. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001 34 (2) 248-253
26. Nanji A A., Jokelainen K, Fotouhinia M et al. Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. Am J Physiol Gastrointest Liver Physiol 2001 281 (6) G1348-G1356
27. Feldstein A E., Canbay A, Angulo P et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003 125 (2) 437-443
28. Barreyro F J., Kobayashi S, Bronk S F., Werneburg N W., Malhi H, Gores G J. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem 2007 282 (37) 27141-27154
29. Cazanave S C., Mott J L., Elmi N A. et al. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 2009 284 (39) 26591-26602
30. Malhi H, Bronk S F., Werneburg N W., Gores G J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006 281 (17) 12093-12101
31. Feldstein A E., Werneburg N W., Li Z, Bronk S F., Gores G J. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 2006 290 (6) G1339-G1346
32. Malhi H, Barreyro F J., Isomoto H, Bronk S F., Gores G J. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007 56 (8) 1124-1131
33. Meriden Z, Forde K A., Pasha T L. et al. Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2010 8 (3) 289-296, 296, e1e8
34. Canbay A, Higuchi H, Bronk S F., Taniai M, Sebo T J., Gores G J. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002 123 (4) 1323-1330
35. Jaeschke H. Inflammation in response to hepatocellular apoptosis. Hepatology 2002 35 (4) 964-966
36. Faouzi S, Burckhardt B E., Hanson J C. et al. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem 2001 276 (52) 49077-49082
37. Chipuk J E., Moldoveanu T, Llambi F, Parsons M J., Green D R. The BCL-2 family reunion. Mol Cell 2010 37 (3) 299-310
38. Cazanave S C., Gores G J. The liver's dance with death: two Bcl-2 guardian proteins from the abyss. Hepatology 2009 50 (4) 1009-1013
39. Takehara T, Tatsumi T, Suzuki T et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004 127 (4) 1189-1197
40. Hikita H, Takehara T, Shimizu S et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology 2009 50 (4) 1217-1226
41. Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell 2010 140 (5) 619-630
42. Nagata S. Apoptosis by death factor. Cell 1997 88 (3) 355-365
43. Canbay A, Feldstein A E., Higuchi H et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003 38 (5) 1188-1198
44. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores G J. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003 83 (5) 655-663
45. Jiang J X., Mikami K, Venugopal S, Li Y, Török N J. Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol 2009 51 (1) 139-148
46. Elliott M R., Chekeni F B., Trampont P C. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009 461 (7261) 282-286
47. Gregory C. Cell biology: Sent by the scent of death. Nature 2009 461 (7261) 181-182
48. Dranoff J A., Ogawa M, Kruglov E A. et al. Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2004 287 (2) G417-G424
49. Mehal W, Imaeda A. Cell death and fibrogenesis. Semin Liver Dis 2010 30 (3) 226-231
50. Bourd-Boittin K, Basset L, Bonnier D, L'helgoualc'h A, Samson M, Théret N. CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J Cell Mol Med 2009 13 (8A, 8A) 1526-1535
51. Wasmuth H E., Zaldivar M M., Berres M L. et al. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol 2008 48 (2) 208-215
52. Hotchkiss R S., Strasser A, McDunn J E., Swanson P E. Cell death. N Engl J Med 2009 361 (16) 1570-1583
53. Friedman S L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008 88 (1) 125-172
54. Kiener P A., Davis P M., Starling G C. et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 1997 185 (8) 1511-1516
55. Chen J J., Sun Y, Nabel G J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998 282 (5394) 1714-1717
56. Dranoff J A., Wells R G. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology 2010 51 (4) 1438-1444
57. Friedman S L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008 134 (6) 1655-1669
58. Jiang J X., Mikami K, Shah V H., Torok N J. Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism. Hepatology 2008 48 (5) 1497-1505
59. Zhan S S., Jiang J X., Wu J et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006 43 (3) 435-443
60. Watanabe A, Hashmi A, Gomes D A. et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007 46 (5) 1509-1518
61. Imaeda A B., Watanabe A, Sohail M A. et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009 119 (2) 305-314
62. Gäbele E, Mühlbauer M, Dorn C et al. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun 2008 376 (2) 271-276
63. Torok N J. Apoptotic cell death takes its toll. Hepatology 2007 46 (5) 1323-1325
64. Witek R P., Stone W C., Karaca F G. et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009 50 (5) 1421-1430
65. Masuoka H C., Guicciardi M E., Gores G J. Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis 2009 13 (3) 467-475
66. Pockros P J., Schiff E R., Shiffman M L. et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007 46 (2) 324-329
67. Hoglen N C., Anselmo D M., Katori M et al. A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia. Liver Transpl 2007 13 (3) 361-366
68. Baskin-Bey E S., Washburn K, Feng S et al. Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant 2007 7 (1) 218-225
69. Ekert P G., Read S H., Silke J et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol 2004 165 (6) 835-842
70. Tait S W., Parsons M J., Llambi F et al. Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev Cell 2010 18 (5) 802-813
71. Green D R., Evan G I. A matter of life and death. Cancer Cell 2002 1 (1) 19-30
72. Kaufmann T, Jost P J., Pellegrini M et al. Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity 2009 30 (1) 56-66
73. Zender L, Hutker S, Liedtke C et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A 2003 100 (13) 7797-7802
74. Yoon J H., Gores G J. Death receptor-mediated apoptosis and the liver. J Hepatol 2002 37 (3) 400-410
75. Lenert P S. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm 2010 2010 986596
76. Santiago-Raber M L., Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun 2009 33 (3-4) 231-238
77. Fiore G, Piazzolla G, Galetta V, Caccetta L, Schiraldi O, Antonaci S. Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C: relationship with biological and histological disease activities. Microbios 1999 97 (386) 29-38
78. Tagashira M, Yamamoto K, Fujio K et al. Expression of perforin and Fas ligand mRNA in the liver of viral hepatitis. J Clin Immunol 2000 20 (5) 347-353
79. Ibuki N, Yamamoto K, Yabushita K et al. In situ expression of granzyme B and Fas-ligand in the liver of viral hepatitis. Liver 2002 22 (3) 198-204
80. Ehrmann J Jr, Galuszková D, Ehrmann J et al. Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection. Pathol Oncol Res 2000 6 (2) 130-135
81. Pianko S, Patella S, Ostapowicz G, Desmond P, Sievert W. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat 2001 8 (6) 406-413
82. Tang T J., Kwekkeboom J, Laman J D. et al. The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat 2003 10 (3) 159-167
83. Rivero M, Crespo J, Fábrega E et al. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat 2002 9 (2) 107-113
84. Tagami A, Ohnishi H, Hughes R D. Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose. Hepatogastroenterology 2003 50 (51) 742-745
85. Ryo K, Kamogawa Y, Ikeda I et al. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 2000 95 (8) 2047-2055
86. Tagami A, Ohnishi H, Moriwaki H, Phillips M, Hughes R D. Fas-mediated apoptosis in acute alcoholic hepatitis. Hepatogastroenterology 2003 50 (50) 443-448
87. Ribeiro P S., Cortez-Pinto H, Solá S et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004 99 (9) 1708-1717
88. Fox C K., Furtwaengler A, Nepomuceno R R., Martinez O M., Krams S M. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001 21 (4) 272-279
89. Tinmouth J, Lee M, Wanless I R., Tsui F W., Inman R, Heathcote E J. Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver 2002 22 (3) 228-234
90. Strand S, Hofmann W J., Grambihler A et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 1998 4 (5) 588-593
91. Tannapfel A, Kohlhaw K, Ebelt J et al. Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens. Transplantation 1999 67 (7) 1079-1083
92. Strand S, Hofmann W J., Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cellsa mechanism of immune evasion? Nat Med 1996 2 (12) 1361-1366
93. Nagao M, Nakajima Y, Hisanaga M et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 1999 30 (2) 413-421
94. Ito Y, Monden M, Takeda T et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2000 82 (6) 1211-1217
95. Ito Y, Takeda T, Umeshita K et al. Fas antigen expression in hepatocellular carcinoma tissues. Oncol Rep 1998 5 (1) 41-44
96. Lee S H., Shin M S., Lee H S. et al. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 2001 32 (3) 250-256
97. Okano H, Shiraki K, Inoue H et al. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 2003 83 (7) 1033-1043
98. Miura K, Kodama Y, Inokuchi S et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010 139 (1) 323-334, e7